RxDoctor Payments Data

Timothy Elder, MD

Family Medicine · Gainesville, FLNPI 1487898839

Payments from drug & device makers

$3,244,039in general payments, 2019–2025

Across 316 payments — averaging $10,266 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi Pasteur Inc.$2.1M
  • Janssen Research & Development, LLC$432K
  • Seqirus USA Inc$341K
  • Cue Health Inc.$126K
  • AstraZeneca$105K
  • Romark Laboratories, LC$83K
  • plus $15K from 6 others
$3,791in research payments, 2019–2025

Across 23 payments — averaging $164.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi Pasteur Inc.$4K

What the payments were for

  • Food & beverage$177100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,244,039 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$353,215
Medicare patients
641
Services billed
7,330

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban195$179,757
MounjaroTirzepatide140$151,917
OzempicSemaglutide82$112,280
JardianceEmpagliflozin51$60,201
Trelegy ElliptaFluticasone/Umeclidin/Vilanter59$44,163
XareltoRivaroxaban30$39,262
EntrestoSacubitril/Valsartan32$32,719
MyrbetriqMirabegron33$31,684
JanuviaSitagliptin Phosphate29$31,350
FarxigaDapagliflozin Propanediol20$20,715
Xultophy 100-3.6Insulin Degludec/Liraglutide12$17,370
Repatha SureclickEvolocumab12$12,065
Breo ElliptaFluticasone/Vilanterol16$10,934
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$9,765
Tresiba Flextouch U-100Insulin Degludec15$9,677

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Xultophy 100-3.6$50$129,65094 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Shingrix$8,156$67,059106 claims
AstraZenecaFarxiga, Symbicort$105,326$29,84657 claims
AbbVieLinzess$15$8,50716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Gainesville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →